HCC

Expert perspectives on the case of a 70-year-old man who presents and is diagnosed with solitary hepatocellular carcinoma measuring greater than 3cm.

Arndt Vogel, MD, discusses the goals of the IMMUTACE study investigating the efficacy of transarterial chemoembolization with nivolumab in patients with intermediate-stage hepatocellular carcinoma.

Lead investigator Arndt Vogel, MD, discussed the use of immunotherapy in earlier-stage HCC and findings from the IMMUTACE in an interview with Targeted Oncology.

Ghassan K. Abou-Alfa, MD, reviews the liver cancer landscape and the collaboration of Memorial Sloan Kettering Cancer Center with other institutions to further treatments in this setting.

A 77-year-old woman presented to her primary care physician with abdominal pain and fatigue.

The HIMALAYA study has met its primary end point of overall survival improvement in patients with unresectable hepatocellular carcinoma with tremelimumab plus durvalumab.

A 77-year-old woman presented to her primary care physician complaining of abdominal pain and fatigue. Ghassan K. Abou-Alfa, MD, discussed the case with a group of physicians.

Most patients with advanced HCC have resistance to PD-1 monotherapy. In other cancers, response to PD-1 inhibitors has been associated with an inflamed microenvironment with effector T cells and active IFN-α signaling.

In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Phase 1 data indicate that ADP-A2AFP SPEAR T cells are effective and tolerable in patients with advanced hepatocellular carcinoma.

In CheckMate040, single-agent nivolumab achieved durable responses in patients with advanced hepatocelluar carcinoma.

Richard S. Finn, MD and a group of peers discusses that case of a 77-year-old woman who presented to her primary care physician complaining of abdominal pain and fatigue.

Pembrolizumab led to improvement in overall survival compared to placebo in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

During a Targeted Oncology Case-Based Roundtable event, Mark Yarchoan, MD, moderates a discussion about a 77-year-old woman with Child Pugh B and C hepatocellular carcinoma.

The FDA has granted a breakthrough device designation to the NovoTTF-200T System, a tumor treating fields delivery system, for the treatment of unresectable or metastatic liver cancer.

In an interview, Amaia Lujambio, MD discussed the diversity of genomic alterations in hepatocellular and advanced in molecular testing that could shape future understanding of the disease.

A study has shown that high interferon signaling and expression of MHC-II related genes can predict response to therapy is patients with advanced heptocellular carcinoma being treated for the first time.

Atezolizumab given in combination with bevacizumab led to an improvement in overall survival compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma.

Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.

In an interview with Targeted Oncology™, Ming Zhao, MD, discussed how the efficacy of HAIC-FO for the treatment of HCC compares to sorafenib as investigated in the FOHAIC-1 clinical trial.

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discusses the efficacy of tislelizumab in HCC in greater detail, along with safety and the agent’s mechanism of action. 

The Oncoguard Liver liquid biopsy test has demonstrated a high sensitivity and specificy for the detection of hepatocellular carcinoma (HCC), including in patients with early-stage HCC.

The indication for nivolumab as a single agent for the treatment of hepatocellular carcinoma in patients previously treated with sorafenib has been withdrawn from the US market.

Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.

A network meta-analysis looking at 4 studies that assessed atezolizumab/bevacizumab compared to lenvatinib showed there was not a statistically significant improvement for patients with unresectable hepatocellular carcinoma.